文献速递流行病学与生物统计临床试验与 GCP

三臂非劣效试验中动态借用的自适应先验方法

Self-Adapting Priors for Dynamic Borrowing in Three-Arm Non-Inferiority Trials With Pre-Specified Margin.
PubMed 文献 · Stat Med · 2026-01-01

针对三臂非劣效试验需整合多源异质历史数据的问题,提出两种贝叶斯自适应先验:加性自适应混合先验(ASAM)和累积自适应乘积先验(CSAP),通过自适应权重动态借用与当前试验更兼容的历史研究信息。模拟研究表明,所提方法在控制I类错误率的同时显著提高统计功效。

要点

  • ASAM与CSAP先验通过自适应加权动态借用历史数据,降低异质性影响。
  • 模拟研究显示方法能维持I类错误率控制并大幅提升统计功效。
  • 三臂设计含安慰剂臂可评估检测灵敏度并内部验证参照效应。

核心结论

  • ASAM和CSAP先验为三臂非劣效试验提供灵活稳健的贝叶斯分析框架。
  • 所提方法在控制I类错误率的同时显著提高统计功效。

研究设计与样本

  • 提出两种贝叶斯自适应先验:加性自适应混合先验(ASAM)和累积自适应乘积先验(CSAP)。
  • ASAM构建研究特异性先验并通过自适应加权混合结合。
  • CSAP采用累积乘积公式并赋予自适应研究特异性权重。
  • 通过广泛模拟研究评估方法性能。

主要发现

  • 模拟研究表明所提方法维持适当的I类错误率控制。
  • 模拟研究表明所提方法在统计功效上获得大幅提升。
  • 两种方法通过给与当前试验更兼容的历史研究更高权重来动态借用信息。

临床怎么用

  • 在三臂非劣效试验中可利用ASAM或CSAP先验整合多个历史参照和安慰剂研究数据。
  • 当历史数据异质时,方法可降低不太可比研究的影响。

局限性

  • 仅通过模拟研究评估,未报告实际临床试验应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-inferiority trials play a central role in clinical research by demonstrating that an experimental treatment is not unacceptably worse than an established reference treatment when superiority is unlikely, but the new treatment offers other advantages, such as reduced toxicity, easier administration, lower cost, or improved adherence. These trials are typically designed as active control studies, making historical data from previous clinical trials or real-world evidence readily available. A key challenge, however, is how to appropriately incorporate multiple heterogeneous historical datasets into the design and analysis of a non-inferiority trial, as each source may differ in relevance, quality, and similarity to the current study. Moreover, a conventional two-arm non-inferiority trial lacks a placebo or standard of care control, requiring the reference treatment effect to be justified using external evidence. When ethically and practically feasible, including a placebo arm allows assessment of assay sensitivity and provides internal validation of the reference treatment effect, thereby strengthening the credibility of the non-inferiority conclusion. In this article, we propose two novel Bayesian self-adapting priors, the Additive Self-Adapting Mixture (ASAM) prior and the Cumulative Self-Adapting Product (CSAP) prior, to incorporate information from multiple historical reference and placebo studies in three-arm non-inferiority trials. The ASAM prior constructs study-specific priors and combines them through an adaptively weighted mixture, whereas the CSAP prior uses a cumulative product formulation with adaptive study-specific weights. Both approaches dynamically borrow information by assigning greater weight to historical studies that are more compatible with the current trial while down-weighting less comparable studies, thereby mitigating the impact of between-study heterogeneity. Extensive simulation studies demonstrate that the proposed methods maintain appropriate control of the Type I error rate while achieving substantial gains in statistical power, providing a flexible and robust framework for Bayesian analysis of three-arm non-inferiority trials.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Yuan Y, Tiwari R, et al. Self-Adapting Priors for Dynamic Borrowing in Three-Arm Non-Inferiority Trials With Pre-Specified Margin. Stat Med. 2026. PMID: 42676243. doi:10.1002/sim.70706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。